BidaskClub upgraded shares of Selecta Biosciences (NASDAQ:SELB) from a hold rating to a buy rating in a research report released on Thursday.

Several other research analysts also recently weighed in on SELB. Zacks Investment Research upgraded shares of Selecta Biosciences from a sell rating to a hold rating in a research report on Tuesday, May 15th. Canaccord Genuity increased their price objective on shares of Selecta Biosciences from $30.00 to $40.00 and gave the stock a buy rating in a research note on Wednesday, May 23rd. ValuEngine raised shares of Selecta Biosciences from a sell rating to a hold rating in a research note on Saturday, June 2nd. Janney Montgomery Scott started coverage on shares of Selecta Biosciences in a research note on Wednesday, June 27th. They issued a buy rating and a $33.00 price objective for the company. Finally, Mizuho reissued a buy rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research note on Thursday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $28.25.

Selecta Biosciences stock traded down $0.01 during midday trading on Thursday, reaching $13.58. 557 shares of the company traded hands, compared to its average volume of 73,878. The company has a market cap of $314.44 million, a price-to-earnings ratio of -4.22 and a beta of -3.39. Selecta Biosciences has a 12 month low of $7.95 and a 12 month high of $24.02. The company has a quick ratio of 4.96, a current ratio of 4.96 and a debt-to-equity ratio of 0.87.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.16). Selecta Biosciences had a negative return on equity of 150.84% and a negative net margin of 31,556.04%. sell-side analysts expect that Selecta Biosciences will post -3.13 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in SELB. Wells Fargo & Company MN increased its stake in shares of Selecta Biosciences by 125.8% in the fourth quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock worth $230,000 after purchasing an additional 13,086 shares in the last quarter. Alps Advisors Inc. increased its stake in shares of Selecta Biosciences by 21.0% in the first quarter. Alps Advisors Inc. now owns 29,958 shares of the company’s stock worth $305,000 after purchasing an additional 5,207 shares in the last quarter. BlackRock Inc. increased its stake in shares of Selecta Biosciences by 1.6% in the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock worth $6,420,000 after purchasing an additional 9,749 shares in the last quarter. Artal Group S.A. purchased a new stake in shares of Selecta Biosciences in the first quarter worth $1,274,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Selecta Biosciences by 40.4% in the first quarter. JPMorgan Chase & Co. now owns 612,422 shares of the company’s stock worth $6,240,000 after purchasing an additional 176,111 shares in the last quarter. 48.75% of the stock is owned by hedge funds and other institutional investors.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.